Purpose: A novel molecular imaging agent has been developed recently, which stains tissues of low extracellular pH [pH (low) insertion peptide, pHLIP ® ]. A pH-dependent process of peptide folding and insertion into cell membranes has been found in vitro. Targeting of acidic solid tumours has been demonstrated in vivo using fluorescence and PET labels. Here, we present proof of feasibility studies of pHLIP with a single-photon emission computed tomography (SPECT) label, 99m Tc-AH114567, with focus on preclinical efficacy and imageability.
Introduction
P athological conditions such as cancer, ischaemic stroke and inflammation are associated with increased metabolic activity, hypoxia and other factors resulting in an acidified extracellular microenvironment. [1] Acidosis is considered a cancer hallmark [2] . In solid tumours, the commonly low extracellular pH (pH e ) is caused primarily by poor/irregular perfusion and increased lactic acid secretion even in the presence of oxygen due to a shift towards aerobic glycolysis (Warburg effect [3] ) and also, e.g., by increased pCO 2 [4] . Moreover, extracellular acidity is suggested to correlate with metastatic potential [5] [6] [7] . This makes assessing and monitoring tumour pH e an interesting alternative diagnostic approach compared to cancer cell receptor targeting with the potential of improving therapy [8, 9] . Recently, pHLIP [pH (low) insertion peptide] has been shown to target tissues of low pH [10] [11] [12] . This peptide has been derived from the bacteriorhodopsin C-helix [13] . Three states have been identified for pHLIP: free/monomeric and unstructured in aqueous solution at neutral/basic pH (state I); unstructured and bound to a lipid bilayer surface at neutral/ basic pH (state II); and with α-helical structure and inserted across a lipid bilayer at acidic conditions as in Fig. 1 (state III) [12] . State I is present at physiological pH and G7 μmol/l. Presence of liposomes in vitro leads to a dynamic equilibrium with binding to the bilayer. Lowering the pH below 7 causes protonation of carboxyl groups, increasing peptide hydrophobicity and affinity to the membrane. This promotes the unidirectional, fast (on the order of seconds) and reversible insertion into the membrane with the C terminus pushed through and the N terminus staying outside [10] . This process is accompanied by formation of secondary structure.
Previously, optical labels [10] [11] [12] and a 64 Cu-DOTA PET label [8] [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and positron emission tomography (PET)] had been conjugated to the N terminus of pHLIP to study the agents potential for use in molecular imaging. Two areas of improvement have been identified and are addressed in this paper: transition to singlephoton emission computed tomography (SPECT) and improving the formulation (further detailed below). In subsequent optimisation and proof-of-concept studies, we aim at addressing two more aspects: improving the pharmacokinetics in order to allow a clinically acceptable imaging time window and (2) supporting further the proof-of-concept through improved experimental designs.
The current study primarily explores feasibility of SPECT imaging with pHLIP. Previous studies were based on optical imaging for convenient and low-cost preclinical evaluation and on PET imaging with the potential to transfer to the clinic. Employing a SPECT nuclide like 99m Tc takes advantage of the much wider availability of SPECT scanners in clinics compared to PET. However, the intrinsically lower sensitivity of SPECT needs to be addressed in the imaging agent development. This study reports the proof-of-feasibility study of a 99m Tc-labelled pHLIP comprising synthesis, improved formulation, characterisation in vitro, stability studies in vivo, biodistribution in three tumour xenograft models (normal and with pH e modulation) and preclinical SPECT imaging. Prostate adenocarcinoma (PC-3) and lymph node carcinoma of the prostate (LNCaP) tumours were chosen based on the reported extracellular pH in those tumours and for comparison with the preceding 64 Cu-DOTA-pHLIP work [8] . This was extended by Lewis lung carcinoma (LLC) tumours, which are a well-established model in-house. All tumour models have been assessed for vascularity via the in vivo angiogenesis marker 99m Tc-NC100692 (maraciclatide) and for pH e via in vivo 31 P magnetic resonance spectroscopy (MRS) with 3-aminopropyl phosphonate (3-APP).
Materials and Methods

Peptide Chemistry and Radiochemistry
The following 37-residue pHLIP variant [11] has been synthesised from D -amino acids: ACEQNPIY{WAR YADWLFTTPLLLLDLALLV}DADEGTG (approximate membrane inserting part in curly brackets [9] , see Fig. 1 ), by solidphase peptide chemistry employing a microwave-assisted peptide synthesiser (CEM Liberty) and NovaSyn TGT resin. Yield was satisfactory at 22% overall, and purity was 995% as estimated by liquid chromatography-mass spectrometry analysis. Next, a tetraamine chelator [14] was conjugated to the cysteine side-chain at position 2 yielding precursor AH114567 (see Fig. 1 ). This chelator allows for rapid 99m Tc-labelling at room temperature with a one-step kit, here comprising the reducing agent SnCl 2 with methylene diphosphonic acid, the radiostabiliser sodium para-aminobenzoate and carbonate buffer. [ 99m Tc]pertechnetate from a DRYTEC™ generator (GE Healthcare) was added. The radioactive product 99m Tc-AH114567 contains trans-TcO 2 +1 coordinated to the four chelator amino groups. Purification from excess pertechnetate was done by preparative high-performance liquid chromatography (HPLC; Thames Restek Viva C 4 column, 100×4.6 mm, 5 μm, 300 Å; mobile phase given in the in vivo stability section below). Retention of the labelled product on the HPLC column and adhesion to silanised glass vials was identified as main reason for initially low yields. These preparations were nevertheless used for the first biology experiments (formulation 1). Higher yields were obtained by adding more precursor to the product fraction (formulation 2) giving a final concentration c (AH114567) ≈25 nmol/ml in phosphate-buffered saline with ≈10% (v/v) ethanol. For experiments involving a scintillation counter, the radioactivity concentration (RAC) was adjusted to ≈50 MBq/ml corresponding to c( 99m Tc-AH114567) ≈2.6 pmol/ml. For imaging experiments, a larger RAC of 300-500 MBq/ml was prepared to compensate for subsequent physical decay during transport to the imaging lab (2-3 h) and to alleviate the loss of sensitivity with a gamma camera compared to scintillation counters (additional compensation is through a longer acquisition time and a larger injected volume of radioactive formulation). Thin layer chromatography with saline as mobile phase was used to analyse preparations within minutes after preparation and 2-4 h later. These showed typically ≤2% [ 
Circular Dichroism Measurements
Samples were prepared with c(peptide)=7 μmol/l and c(POPC liposomes)=2 mmol/l [1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC); diameter≤50 nm] in phosphate buffer of 10 mmol/l and pH=8, followed by a ≥10-h equilibration period at room temperature before measurements. An aliquot of each sample was titrated with 0.1 mol/ l hydrochloric acid to pH=3-4. Circular dichroism (CD) spectra of the samples were recorded on a Jasco J-715 spectropolarimeter (0.1 cm quartz cell, 25°C, 260-185 nm).
Preparation of Mouse Models
All animal studies were performed in compliance with the UK Home Office Animals (Scientific Procedures) Act 1986. Male C57BL/6 and male severally compromised immunodeficient (SCID) mice with a typical body weight of 18-25 g were obtained from Charles River, UK. About 10 6 LLC cells (Lewis lung carcinoma [15] , mouse lung, ECACC 90020104) were implanted subcutaneously in the inner right thigh of C57BL/6 mice, about 10 6 PC-3 cells (prostate adenocarcinoma [16] , human prostate, ATCC CRL-1435) in the nape of the neck of SCID mice, and about 4×10 6 LNCaP cells (lymph node carcinoma of the prostate [17] , human prostate, ATCC CRL-1740) in the nape of the neck of SCID mice. Both PC-3 and LNCaP cell suspensions were prepared with 50% (v/v) Matrigel TM for the inoculations. Tumours (one per animal) were allowed to grow to a size of typically 0.2-0.5 g (some tumours up to ≈1 g), corresponding to growth periods of ≈12 days for LLC, ≈30 days for PC-3 and ≈45 days for LNCaP.
Tumour Characterisation I: Vascularisation
The level of vascularisation was estimated from biodistribution of the in vivo angiogenesis marker 99m Tc-NC100692 [18] in tumoured mice at 2 or 5 min p.i. to assess initial delivery and at 24 or 2 h p.i. to assess retention of the agent. This method is explained in more detail in the discussion.
Tumour Characterisation II: pH e
The mean extracellular pH across the whole tumour was measured via . Since the 3-APP signal line width was similar to that of α-NTP, a correction for a potential pH e distribution in tissue [22] was considered and found unnecessary. Few spectra with larger or asymmetric 3-APP lines were excluded as were spectra where the signal intensity ratio of phosphocreatine (PCr) to α-NTP was 90.8 (see, e.g., spectra in [8, 20, [23] [24] [25] ). Assuming that the actual PCr concentration in tumour tissue is negligible, the observed ratio of 0.8 is estimated to correspond to a tumour signal purity of ≈75%. Additionally a considerable phosphomonoester (PME) signal intensity relative to α-NTP was viewed as indicator of a typical tumour spectrum, cf. e.g., [25] . The inorganic phosphate (Pi) signal often was insufficiently resolved and therefore not used to estimate intracellular pH and bioenergetic status [26] .
In Vivo Stability in Rat Plasma
99m Tc-AH114567 formulation (≈20 MBq) was injected i.v. into the tail vein of naive, anaesthetised (isoflurane) rats. Blood was sampled from the vena cava (one rat each at 2 and 30 min p.i., two rats at 60 min p.i.). The plasma fraction was processed via solid phase extraction, followed by dissolution in the starting mobile phase of 30% (v/v) acetonitrile in water with 0.1% trifluoroacetic acid. This was injected into the radio-HPLC system with a Hichrom ACE 5C 4 column (150×4.6 mm, 300 Å). The linear solvent gradient reached 90% (v/v) acetonitrile after 25 min, the flow rate was 1 ml/min, and signals were detected via UV at 254 nm and Fig. 1 . AH114567 is the 37-amino acid pHLIP sequence with a tetraamine chelator ("ch") coupled to the cysteine sidechain near the N terminus (see inset). At low extracellular pH, the peptide inserts into the cell membrane with the C terminus pushed into the cytoplasm, the central part of pHLIP forming an α-helix residing in the membrane, and the N terminus remaining in the interstitium.
subsequently by a scintillation counter. Mean and standard deviation (SD) values are from two independent studies.
Biodistribution
Each conscious mouse was injected with 99m Tc-AH114567 formulation (0.1 ml, 1-5 MBq, towards higher injected radioactivity in case of formulation 2) as an intravenous bolus into a tail vein. At predefined time points post-injection (p.i.) animals were euthanized, and the following organs and tissues taken: bladder (including urine), blood, bone, brain, faeces, fat, heart, intestines (small and large, including contents), kidneys, liver (together with gall bladder), lungs, muscle, skin, spleen, stomach, thyroid, tumour and voided urine. These organs and tissues, the injection site and the remaining carcass were then assayed for radioactivity in an automatic scintillation counter. Results are presented as "% ID" (fraction of the injected dose) and "% ID/g" (% ID normalised to the sampled organ or tissue weight) as function of time p.i.
Biodistribution/pH e Modulation Study
Specificity was tested in biodistribution studies via pH e modulation. Standard drinking water was supplemented with 200 mmol/l NaHCO 3 provided ad libitum for 5 days prior to administration of 99m Tc-AH114567 and dissection. This regimen is likely to raise the pH e of tumours by ≈0.25-0.3 pH units [27] . However, one study reports no significant difference [8] , and another one a difference of 0.9 pH units [23] .
Small-Animal SPECT/CT Imaging
Preclinical SPECT/computed tomography (CT) whole-body imaging of LLC tumoured mice was performed after the same preparation as for biodistribution studies, except that the 99m Tc-AH114567 dose was larger (0.3 ml, 80-130 MBq), and administration was done as 2 min infusion 2-6 h after radiosynthesis and formulation (improved formulation 2 only). Anaesthesia, respiration and temperature control were the same as in the MRS experiments. Acquisition of images was performed on an Inveon multimodality scanner [28] (Siemens Healthcare) and reconstruction with Cobra (Exxim Computing Corporation). Spiral CT images (40 kVp, 0.5 mA, fan beam, two bed positions and 220 rotation steps) were acquired within 4.2 min. In some cases, a standard iodine contrast agent was applied combined with a tube voltage of 80 kVp. Filtered backprojection reconstruction gave images with 480×922 (transaxial·axial) cubic pixels with 0.1037 mm edge length. SPECT images were acquired 22-24 h post-i. v. injection of 99m Tc-AH114567 within a 91-min frame with 60 projections using two detector heads equipped with five-pinhole (1 mm diameter) collimators. 3D-MAP (maximum a posteriori) reconstruction (10 subsets, eight iterations) without attenuation and scatter correction provided images with 120×380 (transaxial·axial) cubic pixels with 0.5 mm edge length. Image analysis was done with Amide 0.9.2 [29] , including trilinear interpolation and 3D median filtering with a 5×5×5 kernel. Tumour uptake was estimated from an ROI covering the tumour and an ROI covering the whole body except the injection site (w.b.). Image analysis software packages typically output the mean activity concentration c A h iand the volume V of an ROI. Accordingly, the image derived measure comparable to "% ID/g" from biodistribution studies is "% ID/ 
Results
CD spectra of tetraamine-conjugated pHLIP in the presence of POPC liposomes indicate secondary structure formation at low pH only, which agrees with published data for wildtype pHLIP of the same amino acid sequence but without tetraamine chelator [12] . Following this in vitro work, several in vivo studies had been performed using the three described tumour mouse models. Angiogenesis was explored via initial and late tumour uptake of 99m Tc-NC100692. The corresponding retention values are given in Table 1 . The uptake decreases with time as expected. When comparing PC-3 and LNCaP, the initial tumour uptake is not different statistically, but at 24 h p.i., it decreases much more in PC-3 than in LNCaP (Student's t test, P=0.002).
Figure 2a displays the 31 P-MR spectrum of an LLC tumour of 10 mm diameter after 3-APP injection. Note the relatively strong PME and Pi peaks and the weak PCr peak typical for tumour tissue. The chemical shift difference between 3-APP and α-NTP translates to pH e =6.89 in the example. The scatter plot in Fig. 2b shows all pH e results. Mean and SD values are summarised in Table 2 together with P values of Student's t tests.
Rat plasma radio-HPLC traces show integrated signals of the parent compound of (85±7)% at 2 min p.i., (87±2)% at 20 min p.i. and (86±6)% at 60 min p.i. compared to (91±7)% for the spiked phantom sample. The remaining signal intensity is predominantly from a peak at the retention time of pertechnetate.
Tables with 99m Tc-AH114567 biodistribution results (uptake in blood, liver+gall bladder, lung, muscle, and tumour in % ID/g; uptake in bladder + all excreted urine, faeces, kidneys, large intestines, liver+gall bladder, spleen, stomach, and small intestines in %ID; tumour and body weights) are provided as Electronic supplementary material. Key data are plotted as follows. Figure 3 displays the pharmacokinetics in blood and tumour in all three evaluated models from 2 min to 24 h p.i. Initial blood uptake is typically 45% ID/g decreasing steadily to ≈1-2% ID/g at 24 h p.i. Tumour uptake is fairly constant from 1 or 2 h p.i. Confidence intervals (CI) of the ratios calculated via Fieller method [36] up to 24 h p.i. This is also shown in Fig. 4 , which illustrates that tumour uptake data aggregated from 4 to 24 h p. Tc-AH114567 uptake in LLC and in PC-3 and 64 Cu-DOTA-pHLIP uptake in PC-3 are similar. The LLC tumour/blood uptake ratio is significantly higher due to a lower measured uptake in blood, possibly due to the different mouse strain of this in-house established model compared to the PC-3 and LNCaP models, which were set up with SCID mice as in [8] . When comparing the LNCaP to the PC-3 model, the 64 Cu-DOTA-pHLIP data do not show a statistically significant tumour uptake or tumour/blood uptake ratio difference, whereas the 99m Tc-AH114567 data show significantly higher values for LNCaP tumours. Figure 5 shows retention and clearance of 99m Tc-AH114567 (and potential metabolites) through liver and kidney in C57BL/6 mice. The same pattern is observed in SCID mice (see Electronic supplementary material). Renal excretion is most pronounced, but hepatobiliary excretion is also significant. Uptake in liver is high at a 25-15% ID level over the first 24 h p.i. Kidney uptake levels peak at 4 to 8 h p.i. at 10% ID followed by a more rapid washout than in liver towards 3% ID at 24 h p.i.
Uptake in other organs and tissues (see Electronic supplementary material for details) can be summarised as follows. Muscle uptake is initially about 1% ID/g decreasing to ≈0.5% ID/g at 24 h p.i. The lung/blood uptake ratio is initially ≈3, then ≈2 at 4 h p.i. and ≈1 at 24 h p.i. Spleen and stomach uptake is always G2% ID each, and skin uptake is in the range of 3-8% ID. Uptake in bone is found at typically 2-3% ID, in thyroids usually G0.4% ID, in brain initially ≈0.5% ID decreasing gradually to ≈0.1% ID at 24 h p.i.
Formulations 1 and 2 (the latter with cold precursor added after purification) were compared in biodistributions in the LLC model, and no statistically significant differences were observed.
Biodistribution results at 24 h p.i. with pH e modulation by bicarbonate per os are given in Table 3 . This is compared to data from [8] at 4 h p.i. The difference in time is of no concern with regards to tumour tissue since the uptake is apparently stable during that period of time, vide supra. For LNCaP and PC-3, a reduced uptake is observed upon bicarbonate treatment, while the difference was not statistically significant for the two LLC studies.
The SPECT/CT images of 99m Tc-AH114567 in Fig. 6 confirm predominant uptake in liver, kidneys and bladder at ≈1 day p.i. Within kidneys, activity clearly accumulates in the cortex (see figures in Electronic supplementary material). Considerable uptake is found in LLC tumours with (3.8± 0.9)% ID/mL and a tumour/muscle ratio of 4.2±2.8 as estimated from images (N=5). The three views of the tumour in Fig. 6 suggest a somewhat heterogeneous distribution profile with reduced uptake in the tumour centre. Furthermore, no significant uptake is found in brain, but there is some in the region of salivary and thyroid glands and near nose and mouth. Due to a technical problem, the radiochemical purity (RCP) for this preparation was measured only ≈24 h p.i., but it was still high at ≥85%.
Discussion
In vitro CD spectra and in vivo metabolism were used to characterise the imaging agent. The CD spectra confirm that pH-dependent conformational changes and bilayer insertion properties of the pHLIP agent are maintained after conjugation with the tetraamine chelator. Labelling with 99m Tc ions further affects the molecular charge, but since the chelate is conjugated to the non-inserting N terminus, the Tc labelling might have little effect on the membrane insertion.
The metabolism data demonstrate that 99m Tc-AH114567 remains intact in the blood of living rats up to at least 1 h p.i. This covers the main period of delivery of pHLIP from blood to tumour tissue in mice (see also discussion of tumour uptake below).
Next, the characterisation of the biological models is discussed, which were used in the in vivo studies. The initial (initial equilibrium) tumour uptake observed for the angiogenesis marker 99m Tc-NC100692 is similar for all tumour types. The increased 99m Tc-NC100692 retention in LNCaP compared to PC-3 indicates higher vascularity for LNCaP. The LLC data also suggest a high level of vascularity, although this conclusion is less robust due to the earlier sampling time point (4 h p.i.). Furthermore, the pH e data show that LNCaP tumours are more acidic than PC-3 tumours in agreement with published results [8] . Novel pH e data on LLC tumours are similar to those of PC-3 tumours, both data sets being significantly different to that of LNCaP tumours (see Fig. 2 ). In conclusion, LLC and PC-3 may be grouped as "less acidic (less aggressive)" tumour types and LNCaP as "more acidic (more aggressive)", while both LNCaP and LLC are more vascularised. The two potential LLC pH e outliers at pH≈6.5 (see Fig. 2b ) do not affect this overall picture. However, they indicate that the study design could be improved by performing SPECT imaging, pH e and biodistribution measurements in the same animals instead of employing separate batches (in [8] , pH e and biodistribution were indeed measured in the same animals). In addition, note that the spatial resolution for the pH e measurements via the 31 P MRS method is practically limited to the whole tumour with the technology employed. Thus, the 31 P MRS measured pH e is only an indicator of the pH at the site of pHLIP membrane insertion on cell membranes. The local pH e near cell membranes may be expected to be even lower than the bulk pH e measured here.
The main focus of this study is on 99m
Tc-AH114567 biodistribution and SPECT imaging, which is discussed next. Tumour uptake of 99m Tc-AH114567 is fairly constant from 1 or 2 h p.i. to 24 h p.i., while 99m Tc (in parent and potential metabolites) is steadily cleared from blood. Similar uptake values are obtained from SPECT images. In some images, an apparently heterogeneous uptake of AH114567 within a relatively large tumour (see Fig. 6 ) indicates necrotic regions. This needs to be explored further in subsequent studies employing, e.g., histology and autoradiography.
Systemic clearance through and retention in both the hepatobiliary and renal systems is observed, and it might be possible to shift the excretion route towards a more favourable clearance profile through modification of 99m Tc-AH114567. This would be one of the objectives for optimisation of this tracer. For all other organs and tissues like muscle and lung, the biodistribution data suggest imageability of tumours with Tc-AH114567 at 24 h p.i. Bicarbonate treatment resulted in the expected decrease of 99m Tc-AH114567 uptake in tumour in case of LNCaP (the more acidic tumour type) and possibly PC-3 (P from t test is close to 0.05). The observation with LNCaP tumours is consistent with that reported for 64 Cu-DOTA-pHLIP [8] , while PC-3/bicarbonate data are reported for the first time for pHLIP. In contrast to LNCaP and PC-3, a decrease in pHLIP uptake was not observed in LLC tumours. A possible explanation is the decreasing pH sensitivity of pHLIP membrane insertion with increasing tumour pH e . Note that the average pH e is 96.5 in the employed tumour models, and the bicarbonate treatment is expected to increase the pH e further. On the other hand, the pK of membrane insertion of wild-type pHLIP (same amino acid sequence as in AH114567) is about 6.0 [13, 30] ). Thus, bicarbonate treatment is expected to have the greatest effect at pH=6, Cu-DOTA-pHLIP, 4 h p.i. [8] 71% (PG0.005; CI: 38%, 88%)
The uptake ratio (=tumour uptake difference relative to the standard
with uptake values u in case the P value of Student's t test (two-tailed, unpaired) is G0.05 or very close to 0.05. Otherwise, only the P value is shown. 95% confidence intervals (CI) of the ratios are calculated employing the Fieller method [36] . See Electronic supplementary material for the detailed uptake data used to calculate the tumour uptake ratios listed here declining somewhat towards acidic LNCaP tumours and being rather small for less acidic PC-3 and LLC tumours. Note that the pHLIP retention curve as function of pH e is non-linear and that a similar absolute bicarbonate-induced pH e shift is assumed in all tumours. Thus, the statistical power with N=3 may be insufficient to monitor changes in pHLIP retention for less acidic LLC and PC-3 tumours.
With regards to bicarbonate treatment and MRS pH e measurements, it is conceivable that these measured pH e values show a larger relative variability than the biodistribution uptake results. Note also that there is no statistically significant pH e difference in LNCaP tumours with/without bicarbonate treatment in the previously published PET study (see data tables in [8] ). Again, the number of animals may have been insufficient to show the expected difference in pH e while it was sufficient for the presumably more precise pHLIP uptake measurements showing significant differences with/without bicarbonate treatment for both 64 Cu-DOTA-pHLIP and 99m Tc-AH114567. Finally, note that there are conflicting reports on the measured pH e change with oral bicarbonate treatment (see "Materials and Methods") suggesting that there might be unknown influencing factors and the method may not be very robust despite the simple concept.
The above results on pH e and pHLIP uptake excluding the bicarbonate related results are combined in Fig. 7 using group mean and SD. Evaluating 99m Tc-AH114567 in these three models (i.e., without control measurements) can be regarded sufficient to verify that the concept of this imaging agent proven in vitro also holds true in vivo. The 99m Tc-AH114567 data points in Fig. 7 are based on the abscissa and ordinate values from different animal batches. In contrast, both pH e and pHLIP uptake are from the same animals in case of the previously published 64 Cu-DOTA-pHLIP data [8] . Regardless of these technical differences, this plot illustrates correlation between tumour extracellular acidity and pHLIP uptake for both tracers (P=0.039 for all data shown, Pearson, one-tailed). Differences for each parameter within the LNCaP tumour subset (3 points) and the PC-3 tumour subset (2 points) could be due to several reasons, including, e.g., different passage numbers of the inoculated tumour cells for all studies including the two LNCaP batches in the PET study (personal communication). Nevertheless, the overall trend of positive correlation between pHLIP tumour uptake and extracellular acidity is consistently observed for (a) the 64 Cu-DOTA-pHLIP data alone, (b) the 99m Tc-AH114567 data alone, and (c) all displayed data combined.
The second most important factor governing in vivo imageability of labelled pHLIP is blood clearance of pHLIP and its labelled metabolites. The observed clearance is slow, which probably reflects strong binding of pHLIP to red blood cells and/or plasma proteins. With 99m Tc-AH114567, clearance appears to be somewhat slower than for 64 Cu-DOTA-pHLIP (about two times higher level in blood at 4 h p.i. and three to eight times higher levels in liver at 4 and 24 h p.i. for 99m Tc-AH114567) [8] . Liver uptake is also much lower for optically labelled pHLIP [11] compared to 99m Tc-AH114567. The reason might be (a) stronger binding of 99m Tc-AH114567 to red blood cells and/or plasma proteins and (b) slightly different metabolism profiles.
As a measure of imageability and guide towards a suitable imaging time window, the tumour uptake and clearance from blood may be combined as tumour/blood ratio. Requiring, e.g., a ratio ≥1.2 means that imaging would have to commence ≥12 h p.i. for mildly acidic tumours like LLC. For logistical reasons, ≈22 h p.i. was chosen in this study.
The biodistribution data furthermore show that although there is very strong SPECT background signal to be expected in the abdomen, the uptake in muscle and skin is negligible at practically all times compared to tumour tissues. Therefore, a tumour in the neck or in the extremities should be easily discernible in SPECT images according to the biodistribution profile. This is indeed found in pHLIP SPECT images acquired in this study with tumour hotspots clearly visible.
SPECT signal near nose and mouth can be attributed to contamination by excreted activity during the 1 day between 99m Tc-AH114567 administration and imaging. A more pronounced signal is observed in the throat region of some animals, probably in the salivary or thyroid glands. Pertechnetate (i.v.) accumulates in glands (and could also cause signal near nose and mouth) but it clears from thyroid glands within 24 h p.i. (unpublished data in Wistar rat, also e.g., [31, 32] ). Therefore, the observed SPECT signal in those small regions might be from pertechnetate being continuously released from blood at low levels.
When comparing images obtained with the PET and SPECT versions of pHLIP, the main aspects of interest are the administered radioactivity dose, imaging time, and image quality (SNR and contrast for the tumour). Considering the differences in half-lives ( Tc to obtain a similar image SNR. This is a simplified estimate [34] , but one can conclude that the overall imaging sensitivity is of the same order of magnitude for both the SPECT and the PET pHLIP studies. This is confirmed qualitatively when inspecting the published PET and SPECT images. In all those images, tumour hotspots can be clearly identified.
An agent with considerably faster clearance from blood enabling an earlier imaging time window is desirable for the application in the clinic for several reasons like improvements in workflow, dosimetry and image quality.
Conclusion
A robust synthesis and labelling method for production of 99m Tc-pHLIP has been developed, resulting in a good radiolabelling profile including an RCP998% after purification and a high RCP even after 1 day. Furthermore, a new formulation has been devised, which produces a less sticky solution so that less radioactivity remains at injector or injection site after injection. Metabolism data demonstrate a high level of stability of 99m Tc-AH114567 in vivo (rat blood) ensuring sufficient Tc-AH114567 in preclinical tumour models show imageability of tumours outside the abdominal region with adequate radioactivity dose and image quality in mice. The data also support the expectation from preceding studies that pHLIP uptake correlates with tumour extracellular acidity in vivo. This shows feasibility of this new kind of SPECT imaging, possibly also for other applications outside oncology like inflammation. The main development need for this agent is to optimise blood clearance and membrane insertion properties [30] in order to meet requirements for the clinical application (clinical workflow, dosimetry). Furthermore, it is desirable (a) to increase the number of tumour models and/or devise a more robust control experiment in future studies, and (b) to explore the mechanisms of pHLIP distribution and pharmacokinetics in the tumour tissue more closely by histopathology using advanced methods as described in [35] . Some of these aspects are intended to be explored in a subsequent study on the optimisation of this diagnostic imaging agent. 
